Follow this preprint
Risk of Myocarditis after Covid-19 mRNA Vaccination: Impact of Booster Dose and Dosing Interval
View ORCID ProfileStéphane Le Vu, View ORCID ProfileMarion Bertrand, View ORCID ProfileMarie-Joëlle Jabagi, View ORCID ProfileJérémie Botton, View ORCID ProfileAlain Weill, View ORCID ProfileRosemary Dray-Spira, View ORCID ProfileMahmoud Zureik
doi: https://doi.org/10.1101/2022.07.31.22278064
Now published in Nature Communications doi: 10.1038/s41467-024-52038-6
Stéphane Le Vu
1EPIPHARE Scientific Interest Group in Epidemiology of Health Products (French National Agency for the Safety of Medicines and Health Products - ANSM, French National Health Insurance - CNAM), Saint-Denis, France
Marion Bertrand
1EPIPHARE Scientific Interest Group in Epidemiology of Health Products (French National Agency for the Safety of Medicines and Health Products - ANSM, French National Health Insurance - CNAM), Saint-Denis, France
Marie-Joëlle Jabagi
1EPIPHARE Scientific Interest Group in Epidemiology of Health Products (French National Agency for the Safety of Medicines and Health Products - ANSM, French National Health Insurance - CNAM), Saint-Denis, France
Jérémie Botton
1EPIPHARE Scientific Interest Group in Epidemiology of Health Products (French National Agency for the Safety of Medicines and Health Products - ANSM, French National Health Insurance - CNAM), Saint-Denis, France
2Faculté de Pharmacie, Université Paris-Saclay, 92296, Châtenay-Malabry, France
Alain Weill
1EPIPHARE Scientific Interest Group in Epidemiology of Health Products (French National Agency for the Safety of Medicines and Health Products - ANSM, French National Health Insurance - CNAM), Saint-Denis, France
Rosemary Dray-Spira
1EPIPHARE Scientific Interest Group in Epidemiology of Health Products (French National Agency for the Safety of Medicines and Health Products - ANSM, French National Health Insurance - CNAM), Saint-Denis, France
Mahmoud Zureik
1EPIPHARE Scientific Interest Group in Epidemiology of Health Products (French National Agency for the Safety of Medicines and Health Products - ANSM, French National Health Insurance - CNAM), Saint-Denis, France
3University Paris-Saclay, UVSQ, University Paris-Sud, Inserm, Anti-infective evasion and pharmacoepidemiology, CESP, Montigny le Bretonneux, France
![Loading Loading](https://www.medrxiv.org/sites/all/modules/contrib/panels_ajax_tab/images/loading.gif)
Posted August 01, 2022.
Risk of Myocarditis after Covid-19 mRNA Vaccination: Impact of Booster Dose and Dosing Interval
Stéphane Le Vu, Marion Bertrand, Marie-Joëlle Jabagi, Jérémie Botton, Alain Weill, Rosemary Dray-Spira, Mahmoud Zureik
medRxiv 2022.07.31.22278064; doi: https://doi.org/10.1101/2022.07.31.22278064
Now published in Nature Communications doi: 10.1038/s41467-024-52038-6
Subject Area
Subject Areas
- Addiction Medicine (408)
- Allergy and Immunology (721)
- Anesthesia (214)
- Cardiovascular Medicine (3047)
- Dermatology (258)
- Emergency Medicine (456)
- Epidemiology (12965)
- Forensic Medicine (12)
- Gastroenterology (849)
- Genetic and Genomic Medicine (4780)
- Geriatric Medicine (441)
- Health Economics (747)
- Health Informatics (3032)
- Health Policy (1097)
- Hematology (405)
- HIV/AIDS (953)
- Medical Education (450)
- Medical Ethics (119)
- Nephrology (492)
- Neurology (4553)
- Nursing (243)
- Nutrition (673)
- Oncology (2367)
- Ophthalmology (667)
- Orthopedics (264)
- Otolaryngology (332)
- Pain Medicine (297)
- Palliative Medicine (86)
- Pathology (512)
- Pediatrics (1232)
- Primary Care Research (516)
- Public and Global Health (7141)
- Radiology and Imaging (1589)
- Respiratory Medicine (941)
- Rheumatology (456)
- Sports Medicine (396)
- Surgery (506)
- Toxicology (63)
- Transplantation (218)
- Urology (188)